Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum
钙依赖性蛋白激酶 1 作为弓形虫和微小弯曲菌的药物靶点
基本信息
- 批准号:8288293
- 负责人:
- 金额:$ 99.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2015-06-30
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAffinityAnimal Disease ModelsAnimal ModelAnimalsBindingBinding SitesBioavailableBiological AssayCell Culture TechniquesCellsChemicalsComplexConsumptionCryptosporidiosisCryptosporidiumCryptosporidium parvumDataDevelopmentDiseaseDrug Delivery SystemsDrug KineticsEvaluationFoodGatekeepingHomologous GeneHumanInfectionInvadedKnowledgeLeadLibrariesLigandsLightMammalian CellMusOrganismParasitesPharmaceutical PreparationsPhosphotransferasesPositioning AttributeProcessPropertyProtein KinaseProteinsProtozoaRelative (related person)ResistanceSideStructureSynthesis ChemistryToxic effectToxoplasmaToxoplasma gondiiToxoplasmosisWaterWorkanalogbasecalcium-dependent protein kinasedesignfollow-upinhibitor/antagonistkinase inhibitormeetingsmutantnovel therapeuticsobligate intracellular parasitepre-clinicalscaffold
项目摘要
DESCRIPTION (provided by applicant):
New therapeutics are needed for infections caused by Cryptosporidium parvum and Toxoplasma gondii. Calcium dependent protein kinase 1 (CDPK1) of T. gondii is thought to be critical for the invasion process of T. gondii and thus is a drug target for toxoplasmosis. By inference, the homologous CDPK of C. parvum is likely to be critical for infection by cryptosporidium. We have solved the crystal structures of TgCDPK1 and CpCDPK1 and have shown the active sites are susceptible to "bumped" kinase inhibitors (BKI) that do not inhibit mammalian kinases. This differential sensitivity is due to the absence of a bulky gatekeeper side chain in the ATP binding site of both TgCDPK1 and CpCDPK1 that is present in mammalian protein kinases. Thus, these BKI offer tremendous selectivity for inhibition of TgCDPK1 & CpCDPK1 vs. human kinases. Furthermore, BKI compounds have shown minimal toxicity in mice when administered in the course of other work. Our preliminary results show that multiple BKI compounds based on a known scaffold can inhibit TgCDPK1 & CpCDPK1 and also inhibit T. gondii and C. parvum cell invasion at low-mid nanomolar concentrations. Expression of a mutant TgCDPK1 with a Met gatekeeper in T. gondii cells leads to resistance to the BKI effect, demonstrating the BKI inhibits cell entry via CDPK1. We will develop compounds that are orally bioavailable, sufficiently potent, lack toxicity, and cure animal models of T. gondii and/or C. parvum. By the end of this project we expect to identify and characterize 2 to 4 leads for evaluation as potential drugs for cryptosporidiosis and toxoplasmosis. This project will initiate development of new drugs to treat diseases caused by two parasitic protozoa, Cryptosporidium and Toxoplasma that are commonly transmitted by consumption of impure food or water. We have identified a class of chemical compounds that specifically inhibit a particular protein used by these parasites to invade human cells. We will design and characterize compounds of this class that are nontoxic to humans but effective in treating infection.
Relevance: This project will initiate development of new drugs to treat diseases caused by two parasitic protozoa, Cryptosporidium and Toxoplasma, that are commonly transmitted by consumption of impure food or water. We have identified a class of chemical compounds that specifically inhibit a particular protein used by these parasites to invade human cells. We will design and characterize compounds of this class that are nontoxic to humans but effective in treating infection.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(8)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ETHAN A MERRITT其他文献
ETHAN A MERRITT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ETHAN A MERRITT', 18)}}的其他基金
Drug Design Targeting ProRS in Anaerobic Parasites
针对厌氧寄生虫中 ProRS 的药物设计
- 批准号:
9091419 - 财政年份:2015
- 资助金额:
$ 99.28万 - 项目类别:
MEDICAL STRUCTURAL GENOMICS OF PATHOGENIC PROTOZOA
致病原虫的医学结构基因组学
- 批准号:
8362112 - 财政年份:2011
- 资助金额:
$ 99.28万 - 项目类别:
MEDICAL STRUCTURAL GENOMICS OF PATHOGENIC PROTOZOA
致病原虫的医学结构基因组学
- 批准号:
8362415 - 财政年份:2011
- 资助金额:
$ 99.28万 - 项目类别:
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum
钙依赖性蛋白激酶 1 作为弓形虫和微小弯曲菌的药物靶点
- 批准号:
7937610 - 财政年份:2010
- 资助金额:
$ 99.28万 - 项目类别:
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum
钙依赖性蛋白激酶 1 作为弓形虫和微小弯曲菌的药物靶点
- 批准号:
8097594 - 财政年份:2010
- 资助金额:
$ 99.28万 - 项目类别:
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum
钙依赖性蛋白激酶 1 作为弓形虫和微小弯曲菌的药物靶点
- 批准号:
8688133 - 财政年份:2010
- 资助金额:
$ 99.28万 - 项目类别:
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum
钙依赖性蛋白激酶 1 作为弓形虫和微小弯曲菌的药物靶点
- 批准号:
8485534 - 财政年份:2010
- 资助金额:
$ 99.28万 - 项目类别:
MEDICAL STRUCTURAL GENOMICS OF PATHOGENIC PROTOZOA
致病原虫的医学结构基因组学
- 批准号:
8170019 - 财政年份:2010
- 资助金额:
$ 99.28万 - 项目类别:
Prediction of Protein Crystallization and Diffraction Quality
蛋白质结晶和衍射质量的预测
- 批准号:
7707893 - 财政年份:2009
- 资助金额:
$ 99.28万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 99.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 99.28万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 99.28万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 99.28万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 99.28万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 99.28万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 99.28万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 99.28万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 99.28万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 99.28万 - 项目类别:
Continuing Grant